New cancer drug enters human testing for Tough-to-Treat tumors
NCT ID NCT06460961
Summary
This is the first human study of a new cancer drug called MK-6837. Researchers are testing it alone and combined with an existing immunotherapy (pembrolizumab) in 168 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see early signs of whether the drug helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health System Morristown Medical Center ( Site 4001)
Morristown, New Jersey, 07960, United States
-
Princess Margaret Cancer Centre ( Site 2001)
Toronto, Ontario, M5G 2M9, Canada
-
Providence Portland Medical Center ( Site 4002)
Portland, Oregon, 97213, United States
-
Sheba Medical Center-ONCOLOGY ( Site 3001)
Ramat Gan, 5265601, Israel
-
South Texas Accelerated Research Therapeutics (START) ( Site 4003)
San Antonio, Texas, 78229, United States
-
The Alfred Hospital ( Site 1001)
Melbourne, Victoria, 3004, Australia
-
Westmead Hospital ( Site 1002)
Westmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.